Iron Uptake and Mucormycosis Pathogenesis
Iron Uptake and Mucormycosis Pathogenesis
批准号:
7383193
负责人:
ASHRAF S. IBRAHIM
金额:
$26.71万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2011-01-31
关键词:
AffectAffinityAgingAngioinvasionAnimal ModelAnimalsAntifungal TherapyBiological AssayBlood VesselsCell LineCellsChelating AgentsClinicalComplementConditionDebridementDevelopmentDiabetes MellitusDiabetic KetoacidosisDiabetic mouseDiseaseDown-RegulationElementsEnd PointEndothelial CellsEnvironmentFunctional disorderGenerationsGenesHematogenousHistologyHost DefenseImmune responseImmunocompromised HostIn VitroIncidenceInfectionInvadedInvestigationIronIron OverloadLifeMalignant NeoplasmsMediatingMethodsModelingMucormycosisMusNeutropeniaNumbersOperative Surgical ProceduresOrgan TransplantationOrganismOryzaPathogenesisPathogenicityPatientsPenetrationPhagocytesPhagocytosisPharmaceutical PreparationsPolymerase Chain ReactionPopulationPredispositionPrevalenceProcessProductionReportingResearch PersonnelRhizopusRiskRisk FactorsRoleSerumSite-Directed MutagenesisSourceSteroidsTechniquesTestingTimeToxic effectUnited StatesVirulencecell injuryclinically relevantcytokinefungusgenetic manipulationin vivoin vivo Modeliron metabolismmortalitymutantneutrophilnon-diabeticnovelpermeasepreventprogramsreactive oxygen intermediatereceptorresponsesizetissue tropismuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Mucormycosis is a life-threatening infection that occurs in patients immunocompromised by diabetic
ketoacidosis, neutropenia, steroid use, and/or increased serum iron. Because of the rising prevalence of risk
factors, the incidence of mucormycosis has dramatically increased (1300% over 15 years according to one
source). Despite disfiguring surgery and aggressive antifungal therapy, the mortality of mucormycosis
remains >50%, and approaches 100% in patients with disseminated disease. Clearly new strategies to
prevent and treat mucormycosis are urgently needed.
Clinical hallmarks of infection by Rhizopus oryzae, the most common cause of mucormycosis, include the
unique susceptibility of patients with increased available serum iron, the propensity of the organism to invade
blood vessels, and defective phagocytic function, which we hypothesize to be, at least in part, a result of iron
toxicity. These clinical hallmarks underscore the critical role of iron metabolism, as well as interactions with
endothelial cells lining blood vessels, in the organism's virulence strategy. We have found that R. oryzae
damages endothelial cells in vitro and this process is dependent on iron. Additionally, we have cloned the R.
oryzae high affinity iron permease (rFTR1) which scavenges iron from iron-depleted environments such as is
found in the host. Finally we have developed clinically relevant models of infection in diabetic ketoacidotic
mice. We hypothesize that iron uptake, and specifically rFTR1, is essential for R. oryzae to cause infection.
To test this hypothesis, we propose to: 1) characterize the mechanism(s) by which iron regulates R. oryzae-
induced endothelial cell injury; 2) construct an isogenic rftrl null mutant and its corresponding rFTR1
complemented strain jn R. oryzae by site directed mutagenesis; 3) compare the pathogenicity of the
generated rftrl to that of the wild-type and rFTR1 complemented strains in our in vitro and in vivo models of
infection; and 4) elucidate the role of iron in regulating the innate host response to R. oryzae.
Accomplishing these specific aims will define the role of the central elements affecting the establishment
and progression of mucormycosis as it relates to iron uptake. Ultimately, a superior understanding of the
pathogenesis of mucormycosis will enable development of novel therapies for this disease. Completion of
the proposed studies will enable investigation of treatments that block R. oryzae uptake of iron.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10338103
-
项目类别:
-
资助金额:$104.73万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens Supplement
-
批准号:10564958
-
项目类别:
-
资助金额:$3.84万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10728900
-
项目类别:
-
资助金额:$8.31万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10535474
-
项目类别:
-
资助金额:$115.18万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10084265
-
项目类别:
-
资助金额:$102.25万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:9759762
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:10599750
-
项目类别:
-
资助金额:$98.79万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9089918
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9488843
-
项目类别:
-
资助金额:$45.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9755205
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:8020985
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:7896157
-
项目类别:
-
资助金额:$18.12万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:8174480
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2009
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7952233
-
项目类别:
-
资助金额:$0.63万
-
财政年份:2008
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7606192
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2007
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment
-
批准号:10666383
-
项目类别:
-
资助金额:$55.48万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Antifungal Strategies for Lethal Mucormycosis
-
批准号:7268002
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:8685093
-
项目类别:
-
资助金额:$35.29万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:7556321
-
项目类别:
-
资助金额:$26.94万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:8889496
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
海外基金